BridgeBio Pharma Inc (FRA:2CL)
€ 26.2 -0.29 (-1.09%) Market Cap: 4.86 Bil Enterprise Value: 5.98 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 45/100

BridgeBio Pharma Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 08:00PM GMT
Release Date Price: €12.9 (-2.27%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Priyanka Grover, [Malcolm Kuno and Chattle Smith] from the team. Our next presenting company is BridgeBio. Presenting on behalf of the company, we have CEO, Neil Kumar.

I want to remind attendees to us to Ask A Question feature in the portal. And if you put more a question in there, I'm happy to ask on your behalf. With that, Neil, take it away.

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, CEO & Director

Thanks, Anupam, for that introduction, and thanks to the Phil and the entire JPM team for the opportunity to present today. I'll refer to slide numbers as I move through here for those of you following along at home with the presentation. Despite some meaningful progress against our pipeline and portfolio in the early stages of 2021, importantly, with our proof-of-concept data in ADH1 as well as our first 2

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot